Zusammenfassung
Autoinflammatorische Erkrankungen präsentieren sich als multisystemische Entzündungen und werden häufig bereits im frühen Kindesalter manifest. Bei wenigen Erkrankungen, wie z. B. dem kürzlich beschriebenen VEXAS-Syndrom (Vakuolen, E1-Enzym, X‑chromosomal, autoinflammatorisch, somatisch) treten die ersten Krankheitssymptome dagegen ausschließlich im Erwachsenenalter auf. Dieser Beitrag beschreibt, inwiefern sich die phänotypische Ausprägung und Schwere einzelner autoinflammatorischer Erkrankungen in Abhängigkeit vom Lebensalter unterscheiden. Zudem werden altersabhängige Differenzen in der Ausbildung von vorliegenden Organschäden aufgezeigt. Neben den hereditären periodischen Fiebersyndromen werden auch das Krankheitsbild der Adenosindesaminase-2-Defizienz, die Interferonopathien, das PFAPA-Syndrom mit periodischem Fieber, aphthöser Stomatitis, Pharyngitis und zervikaler Adenitis sowie das VEXAS- und das Schnitzler-Syndrom beleuchtet.
Abstract
Autoinflammatory diseases present as multisystemic inflammation and often manifest in early childhood. In contrast, in a few diseases, e.g., the recently described VEXAS (vacuoles, E1 enzyme, X‑linked, autoinflammatory, somatic) syndrome, the first symptoms occur exclusively in adulthood. This article describes how the phenotypic expression and severity of individual autoinflammatory diseases differ depending on age. Furthermore, differences in the development of organ damage in children and adults are pointed out. In addition to the hereditary periodic fever syndromes, the clinical picture of deficiency of adenosine deaminase 2, the interferonopathies, periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome as well as VEXAS and Schnitzler syndromes are highlighted.
Literatur
Kallinich T, Hinze C, Wittkowski H (2020) Classification of autoinflammatory diseases based on pathophysiological mechanisms. Z Rheumatol 79:624–638. https://doi.org/10.1007/s00393-020-00794-3
Gattorno M et al (2019) Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 78:1025–1032. https://doi.org/10.1136/annrheumdis-2019-215048
Kallinich T, Orak B, Wittkowski H (2017) Role of genetics in familial Mediterranean fever. Z Rheumatol 76:303–312. https://doi.org/10.1007/s00393-017-0265-9
Park YH et al (2020) Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. Nat Immunol 21:857–867. https://doi.org/10.1038/s41590-020-0705-6
Langevitz P et al (1999) Familial Mediterranean fever: new aspects and prospects at the end of the millenium. Isr Med Assoc J 1:31–36
Yalcinkaya F et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398. https://doi.org/10.1093/rheumatology/ken509
Demirkaya E et al (2016) Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol 43:154–160. https://doi.org/10.3899/jrheum.141249
Kondi A et al (2010) Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. Rheumatology (Oxford) 49:2200–2203. https://doi.org/10.1093/rheumatology/keq252
Padeh S et al (2010) Familial Mediterranean fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 156:985–989. https://doi.org/10.1016/j.jpeds.2009.12.010
Padeh S et al (2010) Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 37:865–869. https://doi.org/10.3899/jrheum.090687
Hentgen V, Grateau G, Stankovic-Stojanovic K, Amselem S, Jeru I (2013) Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? Arthritis Rheum 65:1654–1662. https://doi.org/10.1002/art.37935
Butbul Aviel Y et al (2019) Familial Mediterranean fever is commonly diagnosed in children in Israel with periodic fever aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr 204:270–274. https://doi.org/10.1016/j.jpeds.2018.08.080
Sonmez HE, Batu ED, Bilginer Y, Ozen S (2017) Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. Clin Rheumatol 36:421–425. https://doi.org/10.1007/s10067-016-3421-8
Tanatar A, Karadag SG, Sonmez HE, Cakan M, Aktay Ayaz N (2019) Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit? Rheumatology (Oxford) 58:1818–1821. https://doi.org/10.1093/rheumatology/kez156
Ricci P et al (2020) The grandfather’s fever. Clin Rheumatol 39:585–594. https://doi.org/10.1007/s10067-019-04741-9
Yasar Bilge NS et al (2018) Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis 21:880–884. https://doi.org/10.1111/1756-185X.13259
Brenner R et al (2018) Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatol 70:127–133. https://doi.org/10.1002/art.40344
Altunoglu A et al (2013) Phenotype 2 familial mediterranean fever: evaluation of 22 case series and review of the literature on phenotype 2 FMF. Ren Fail 35:226–230. https://doi.org/10.3109/0886022X.2012.745115
Lainka E et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48:987–991. https://doi.org/10.1093/rheumatology/kep140
Cudrici C, Deuitch N, Aksentijevich I (2020) Revisiting TNF receptor-associated periodic syndrome (TRAPS): current perspectives. Int J Mol Sci. https://doi.org/10.3390/ijms21093263
Lachmann HJ et al (2014) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 73:2160–2167. https://doi.org/10.1136/annrheumdis-2013-204184
Pelagatti MA et al (2011) Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 63:1141–1150. https://doi.org/10.1002/art.30237
Ruiz-Ortiz E et al (2017) Disease phenotype and outcome depending on the age at disease onset in patients carrying the R92Q low-penetrance variant in TNFRSF1A gene. Front Immunol 8:299. https://doi.org/10.3389/fimmu.2017.00299
Poirier O et al (2004) Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness—the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet 12:213–219. https://doi.org/10.1038/sj.ejhg.5201143
Caminero A, Comabella M, Montalban X (2011) Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. Clin Exp Immunol 166:338–345. https://doi.org/10.1111/j.1365-2249.2011.04484.x
Levy R et al (2015) Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever registry. Ann Rheum Dis 74:2043–2049. https://doi.org/10.1136/annrheumdis-2013-204991
Vitale A, Lucherini OM, Galeazzi M, Frediani B, Cantarini L (2012) Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clin Exp Rheumatol 30:943–946
Mensa-Vilaro A et al (2016) Brief report: late-onset cryopyrin-associated periodic syndrome due to myeloid-restricted somatic NLRP3 mosaicism. Arthritis Rheumatol 68:3035–3041. https://doi.org/10.1002/art.39770
Rowczenio DM et al (2017) Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism-UK single center experience. Front Immunol 8:1410. https://doi.org/10.3389/fimmu.2017.01410
Brennenstuhl H et al (2021) Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria. J Inherit Metab Dis. https://doi.org/10.1002/jimd.12412
Drenth JP et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International hyper-IgD study group. Nat Genet 22:178–181. https://doi.org/10.1038/9696
Ter Haar NM et al (2016) The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry. Arthritis Rheumatol 68:2795–2805. https://doi.org/10.1002/art.39763
Ozen S et al (2017) International retrospective chart review of treatment patterns in severe familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/hyperimmunoglobulinemia D syndrome. Arthritis Care Res (Hoboken) 69:578–586. https://doi.org/10.1002/acr.23120
Zhang S (2016) Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J 14:30. https://doi.org/10.1186/s12969-016-0091-7
Navon Elkan P et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931. https://doi.org/10.1056/NEJMoa1307362
Zhou Q et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920. https://doi.org/10.1056/NEJMoa1307361
Lee PY (2018) Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. Front Pediatr 6:282. https://doi.org/10.3389/fped.2018.00282
Zhang B et al (2021) Adult-onset deficiency of adenosine deaminase 2‑a case report and literature review. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05587-w
Pinto B, Deo P, Sharma S, Syal A, Sharma A (2021) Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05711-w
Ombrello AK et al (2019) Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med 380:1582–1584. https://doi.org/10.1056/NEJMc1801927
Caorsi R, Penco F, Schena F, Gattorno M (2016) Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J 14:51. https://doi.org/10.1186/s12969-016-0111-7
Rama M et al (2018) A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet 26:960–971. https://doi.org/10.1038/s41431-018-0130-6
Schepp J et al (2017) Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol 69:1689–1700. https://doi.org/10.1002/art.40147
Crow YJ (2011) Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238:91–98. https://doi.org/10.1111/j.1749-6632.2011.06220.x
Rodero MP, Crow YJ (2016) Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med 213:2527–2538. https://doi.org/10.1084/jem.20161596
de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R (2015) Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 33:823–874. https://doi.org/10.1146/annurev-immunol-032414-112227
Feist E, Brehm A, Kallinich T, Kruger E (2017) Clinical aspects and genetics of proteasome-associated autoinflammatory syndromes (PRAAS). Z Rheumatol 76:328–334. https://doi.org/10.1007/s00393-017-0264-x
Zhang X et al (2015) Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 517:89–93. https://doi.org/10.1038/nature13801
Watkin LB et al (2015) COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 47:654–660. https://doi.org/10.1038/ng.3279
Liu Y et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371:507–518. https://doi.org/10.1056/NEJMoa1312625
Dai Y, Liu X, Zhao Z, He J, Yin Q (2020) Stimulator of interferon genes-associated vasculopathy with onset in infancy: a systematic review of case reports. Front Pediatr 8:577918. https://doi.org/10.3389/fped.2020.577918
Aicardi J, Goutieres F (1984) A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 15:49–54. https://doi.org/10.1002/ana.410150109
Crow YJ et al (2015) Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A 167A:296–312. https://doi.org/10.1002/ajmg.a.36887
Staels F et al (2020) Adult-onset ANCA-associated vasculitis in SAVI: extension of the phenotypic spectrum, case report and review of the literature. Front Immunol 11:575219. https://doi.org/10.3389/fimmu.2020.575219
Jeremiah N et al (2014) Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 124:5516–5520. https://doi.org/10.1172/JCI79100
Picard C et al (2016) Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest 150:e65–71. https://doi.org/10.1016/j.chest.2016.02.682
Rice GI et al (2017) Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease. Neuropediatrics 48:166–184. https://doi.org/10.1055/s-0037-1601449
Namjou B et al (2011) Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun 12:270–279. https://doi.org/10.1038/gene.2010.73
Cantarini L, Vitale A, Bartolomei B, Galeazzi M, Rigante D (2012) Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clin Exp Rheumatol 30:269–271
Cantarini L et al (2017) Diagnostic criteria for adult-onset periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Front Immunol 8:1018. https://doi.org/10.3389/fimmu.2017.01018
Sicignano LL et al (2021) Children and adults with PFAPA syndrome: similarities and divergences in a real-life clinical setting. Adv Ther 38:1078–1093. https://doi.org/10.1007/s12325-020-01576-8
Hofer M et al (2014) International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford) 53:1125–1129. https://doi.org/10.1093/rheumatology/ket460
Beck DB et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628–2638. https://doi.org/10.1056/NEJMoa2026834
Ferrada MA et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS syndrome. Arthritis Rheumatol. https://doi.org/10.1002/art.41743
Tsuchida N et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220089
Arlet JB, Terrier B, Kosmider O (2021) Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 384:2163. https://doi.org/10.1056/NEJMc2102124
Simon A et al (2013) Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 68:562–568. https://doi.org/10.1111/all.12129
Kacar M, Pathak S, Savic S (2019) Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome. Rheumatology (Oxford) 58:vi31–vi43. https://doi.org/10.1093/rheumatology/kez448
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Krusche und T. Kallinich geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
Hans-Iko Huppertz, Bremen
Hanns-Martin Lorenz, Heidelberg
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Krusche, M., Kallinich, T. Autoinflammation – Unterschiede bei Kindern und Erwachsenen. Z Rheumatol 81, 45–54 (2022). https://doi.org/10.1007/s00393-021-01115-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-021-01115-y